DCM
XBI icon

DGS Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

DGS Capital Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223K Sell
1,745
-70
-4% -$8.74K 0.04% 521
2025
Q4 		$221K Buy
+1,815
New +$208K 0.04% 430

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

DGS Capital Management's XBI Position: Q1 2026 in Review

DGS Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 3.9% in Q1 2026, selling an estimated $8.74K and leaving 1,745 shares worth $223K. The position accounts for 0.04% of the portfolio, ranked #521.

DGS Capital Management first reported a position in XBI in Q4 2025 and has held it in 2 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • DGS Capital Management held 1,745 shares of State Street SPDR S&P Biotech ETF worth $223K as of Q1 2026.
  • DGS Capital Management sold 70 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $8.74K.
  • State Street SPDR S&P Biotech ETF made up 0.04% of DGS Capital Management's portfolio in Q1 2026, its #521 holding.
  • DGS Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 2 quarters since.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.